M

Mineralys Therapeutics

Clinical-stage biopharma targeting aldosterone synthesis

Territory Manager

Full-Time
$130k - $165k+ Incentive plans
Mid
Bachelor's
Remote in USA
Remote
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree or equivalent experience is required.
  • Three or more years of pharmaceutical or biotech sales experience is preferred, with other relevant sales experience considered.
  • Specialty sales experience in cardiometabolic products is preferred.
  • Prior launch experience is preferred.
  • A proven track record of achieving or exceeding sales goals and building strong customer relationships is required.
  • Strong clinical acumen and the ability to communicate complex scientific information are required.
  • Territory planning, organizational, and communication skills are required.
  • The candidate must be self-motivated and able to thrive in a fast-paced launch environment.
  • A valid driver's license and willingness to travel within the territory are required.
Responsibilities
  • Develop and maintain a strong understanding of the disease state, clinical data, and relevant treatment guidelines.
  • Build and execute a comprehensive territory business plan aligned with brand strategy, launch priorities, and sales objectives.
  • Drive product adoption and compliant utilization among targeted healthcare providers.
  • Analyze territory trends, customer needs, and competitive activity to identify opportunities and course-correct as needed.
  • Consistently deliver against sales goals, call activity expectations, and launch milestones.
  • Maintain accurate territory reporting and customer relationship management documentation.
  • Execute strategic call plans by translating data and insights into impactful, customer-focused actions.
  • Assess market dynamics and leverage insights for effective territory planning.
  • Build and sustain trusted relationships with healthcare providers, office staff, and key decision-makers.
  • Clearly and compliantly communicate clinical data, product value, access information, and appropriate patient identification.
  • Deliver product presentations and address customer questions with confidence and credibility.
  • Partner with customers to address barriers to patient access and support product pull-through.
  • Partner with cross-functional stakeholders to understand customer needs and elevate the customer and patient experience compliantly.
  • Collaborate with adjacent field partners, including Field Reimbursement Managers, Territory Managers, and Regional Business Directors, to support customer needs and territory objectives.
  • Share insights, learnings, and best practices with field leadership and internal teams, including Marketing, Training, Field Operations, and Analytics.
  • Provide timely market intelligence, customer insights, and competitive updates.
  • Support regional meetings, launch initiatives, and company-sponsored programs.
  • Operate in compliance with company policies, industry regulations, and legal requirements.
  • Demonstrate professionalism, accountability, and ethical conduct in customer interactions.
  • Travel up to 60%.
Desired Qualifications
  • Three or more years of pharmaceutical or biotech sales experience, although other relevant sales experience may be considered.
  • Specialty sales experience in cardiometabolic products.
  • Prior launch experience.

About the company

M

Mineralys Therapeutics

View
Website

Mineralys Therapeutics develops targeted treatments for diseases driven by dysregulated aldosterone to help lower blood pressure. Its lead drug, lorundrostat, is an oral aldosterone synthase inhibitor that blocks the CYP11B2 enzyme to reduce aldosterone production, with high selectivity over cortisol. It is advancing through late-stage trials (Phase 3) to treat hypertension-related conditions, CKD, and potentially OSA, using funds from its IPO to support trials, manufacturing, and commercialization preparation. By focusing on a selective mechanism that avoids large cortisol disruption, Mineralys differentiates itself from older MRAs and aims to address a large potential market, estimated to exceed $200 billion by 2030.

Company Size

51-200

Company Stage

IPO

Headquarters

Radnor Township, Pennsylvania

Founded

2020

Get referred to Mineralys Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted lorundrostat NDA on March 9, 2026, with December 22 PDUFA.
  • Q2 2026 showed commercial readiness: sales hiring, market access, and payer engagement.
  • Lorundrostat posted 52.2% placebo-adjusted UACR reduction in CKD albuminuria at 12 weeks.

What critics are saying

  • AstraZeneca's Baxfendy approved May 18, 2026, grabbing first-mover advantage before Mineralys.
  • December 22, 2026 PDUFA leaves one binary FDA decision; rejection kills the launch.
  • If lorundrostat misses approval, Mineralys becomes a cash-burning single-asset biotech.

What makes Mineralys Therapeutics unique

  • Lorundrostat directly inhibits CYP11B2, targeting aldosterone source instead of receptor blockade.
  • Launch-HTN enrolled 800 patients and showed CKD-aligned blood-pressure and albuminuria reductions.
  • Mineralys now owns lorundrostat royalties and IP after the June 2026 Tanabe buyout.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Hybrid Work Options
  • 401(k) Company Match
  • Wellness Program
  • Mental Health Support
  • Gym Membership

Growth & Insights and Company News

6 month growth

0%

1 year growth

-4%

2 year growth

-1%
Associated Press
Oct 19th, 2026
Mineralys adds Kristine Peterson and Lonnel Coats to board ahead of lorundrostat launch

Mineralys Therapeutics has added Kristine Peterson and Lonnel Coats to its board of directors, the biopharmaceutical company announced on October 19, 2026. The Radnor, Pennsylvania-based company is preparing for the potential approval and commercial launch of lorundrostat, a treatment for uncontrolled or resistant hypertension. Peterson was most recently chief executive officer of Valeritas. She also spent 20 years at Bristol-Myers Squibb and held senior roles at Johnson & Johnson and Biovail. Coats was most recently chief executive officer of Lexicon Pharmaceuticals. He previously led Eisai's North American business and spent eight years at Janssen Pharmaceuticals. Chief executive officer Jon Congleton said their commercial experience will help as Mineralys becomes a commercial-stage company.

GlobeNewswire
Oct 19th, 2026
Mineralys Therapeutics expands its Board of Directors with the appointments of Kristine Peterson and Lonnel Coats.

Mineralys Therapeutics expands its Board of Directors with the appointments of Kristine Peterson and Lonnel Coats. The addition of Ms. Peterson and Mr. Coats brings additional commercial and product launch experience to Mineralys ahead of the December 22 PDUFA target action date for lorundrostat. RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) - Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that Kristine Peterson and Lonnel Coats have been appointed to the Company's Board of Directors. "We are delighted to welcome Kris and Lonnel to our Board of Directors as we prepare for the potential approval and commercial launch of lorundrostat for the treatment of uncontrolled or resistant hypertension," stated Jon Congleton, Chief Executive Officer of Mineralys. "As seasoned leaders who have each built and led commercial organizations, Kris and Lonnel bring deep experience launching and commercializing new therapies across multiple therapeutic areas, including cardiovascular and metabolic disease. We believe their track records of commercial execution, operational leadership and public company board service will make them valuable directors and resources as Mineralys transitions to a commercial-stage organization." "I am honored to join the Mineralys Board of Directors at such a pivotal time for the Company," stated Ms. Peterson. "Having spent much of my career launching new medicines, including in cardiovascular disease, I appreciate the significant unmet need among patients whose hypertension is not controlled with currently available therapies. I look forward to working with the Company's executive team and fellow Board members as Mineralys prepares for the potential commercial launch of lorundrostat." "I am pleased to join the Mineralys Board of Directors," stated Mr. Coats. "Hypertension remains a leading driver of cardiovascular risk, and too many patients are unable to reach their blood pressure goals with currently available treatments. Lorundrostat has significant potential to offer a targeted treatment approach for hypertension driven by dysregulated aldosterone, and I look forward to contributing as the Company advances toward this next chapter." Ms. Peterson is a biopharmaceutical executive with more than three decades of experience in commercial, operational and general management leadership, including launching numerous products across multiple therapeutic areas. She most recently served as Chief Executive Officer of Valeritas, Inc., a commercial-stage medical technology company. Prior to Valeritas, Ms. Peterson served as Company Group Chair of the Biotechnology Group and Executive Vice President of Pharmaceutical Group Strategic Marketing at Johnson & Johnson, where she led commercial, research and development, and biologics manufacturing in oncology, immunology and cell therapy. Prior to Johnson & Johnson, Ms. Peterson served as Senior Vice President, Commercial Operations, of Biovail Corporation and President of Biovail Pharmaceuticals. Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb Company in a variety of senior roles in sales, marketing and general management, including leading its cardiovascular and metabolic disease business unit. Ms. Peterson currently serves as a member of the Board of Directors at ArriVent BioPharma, Inc., Enanta Pharmaceuticals, Inc. and Immunocore Holdings plc. Ms. Peterson also previously served as a member of the board of directors of the Biotechnology Innovation Organization (BIO). Ms. Peterson received her B.S. in Marketing and her M.B.A. from the University of Illinois. Mr. Coats is a biopharmaceutical executive with more than three decades of experience in building and leading commercial pharmaceutical organizations. He most recently served as Chief Executive Officer of Lexicon Pharmaceuticals, Inc. Prior to joining Lexicon, Mr. Coats served in a series of leadership positions, including Chief Executive Officer of North America, at Eisai Inc. and Eisai Corporation of North America, where he oversaw the commercialization of Eisai products in the therapeutic areas of oncology, neurology, gastrointestinal disorders, epilepsy and metabolic disorders. Prior to Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions. Mr. Coats currently serves as a member of the Board of Directors of Relay Therapeutics, Inc. Mr. Coats received his B.S. in Public Administration from Oakland University. About Mineralys Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky. Forward-Looking Statements Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys' current beliefs and expectations and include, but are not limited to, statements regarding the anticipated timing of the Food and Drug Administration's (FDA) review of Mineralys' accepted NDA and the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys' business, including, without limitation: any delays in the FDA's review of Mineralys' accepted new drug application (NDA), including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys' clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA's review of Mineralys' NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of its license agreement with Tanabe on its expected timeframe, or at all; Mineralys' future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys' dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys' ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys' reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys' filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Media Relations Melyssa Weible Elixir Health Public Relations Email: [email protected]

GlobeNewswire
Sep 23rd, 2026
Mineralys Therapeutics' Transform-HTN open-label extension trial data selected for late-breaking presentation at American Heart Association Scientific Sessions 2026.

Mineralys Therapeutics' Transform-HTN open-label extension trial data selected for late-breaking presentation at American Heart Association Scientific Sessions 2026. RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) - Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new long-term efficacy and safety data from the Company's ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL. Details for the Presentation: | Title: | Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension | | Presenter: | Manish Saxena MBBS, Deputy Clinical Co-Director of Queen Mary University of London's William Harvey Heart Centre, and Hypertension Specialist at Barts Health NHS Trust | | Session Time: | Sunday, November 8, 3:30 pm CT | | Session Title: | Old Meds, New Meds and BP Goals: Optimizing Antihypertensive Therapy | | Session Location: | Learning Studio 2, Science and Technology Hall, South Hall | | / | About Transform-HTN Transform-HTN (NCT05968430) is a global open-label extension trial designed to assess the safety, efficacy and tolerability of lorundrostat in participants with hypertension, and includes participants who completed one of three eligible parent studies (Advance-HTN, Launch-HTN or Explore-CKD). Eligible participants were enrolled in the open-label extension study, with a primary endpoint of the change in automated office systolic blood pressure. About Hypertension Having sustained, elevated blood pressure (BP) (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019. Less than 50% of hypertensive patients achieve their BP goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients. About Lorundrostat Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as CKD, OSA and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension. Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile. About Mineralys Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky. Forward-Looking Statements Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys' current beliefs and expectations and include, but are not limited to, statements regarding the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys' business, including, without limitation: any delays in the Food and Drug Administration's (FDA) review of Mineralys' accepted new drug application (NDA), including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys' clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA's review of Mineralys' NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of its license agreement with Tanabe on its expected timeframe, or at all; Mineralys' future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys' dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys' ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys' reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys' filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Media Relations Melyssa Weible Elixir Health Public Relations Email: [email protected]

MarketBeat
Sep 17th, 2026
Insider selling: Mineralys Therapeutics (NASDAQ:MLYS) director sells $85,740.00 in stock.

Insider selling: Mineralys Therapeutics (NASDAQ:MLYS) director sells $85,740.00 in stock. September 17, 2026 Key points. * Director sale: Daphne Karydas sold 3,000 Mineralys Therapeutics shares for approximately $85,740 under a pre-arranged Rule 10b5-1 plan, reducing her direct ownership by 32.61% to 6,200 shares. * Stock and financial performance: MLYS recently traded at $27.98, with a $2.47 billion market capitalization. The company reported a quarterly loss of $2.85 per share, significantly missing the $0.55 consensus estimate. * Analyst outlook: Despite mixed ratings, including hold and sell calls, the stock has a consensus "Moderate Buy" rating and an average price target of $48.80; institutional investors own 84.46% of the shares. * MarketBeat previews the top five stocks to own by October 1st. Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total value of $85,740.00. Following the completion of the transaction, the director directly owned 6,200 shares in the company, valued at approximately $177,196. This represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Mineralys Therapeutics price performance. Shares of NASDAQ:MLYS traded up $0.44 during mid-day trading on Thursday, reaching $27.98. The stock had a trading volume of 1,141,567 shares, compared to its average volume of 1,267,498. The business's 50 day moving average price is $27.15 and its 200 day moving average price is $27.12. Mineralys Therapeutics, Inc. has a 1 year low of $22.30 and a 1 year high of $47.65. The company has a market cap of $2.47 billion, a P/E ratio of -6.60 and a beta of 0.68. The company has a current ratio of 34.46, a quick ratio of 34.46 and a debt-to-equity ratio of 0.18. Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($2.30). Research analysts expect that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current fiscal year. Hedge funds weigh in on Mineralys Therapeutics. A number of large investors have recently made changes to their positions in the company. Timothy G. Youngquist 2020 Irrevocable Trust bought a new stake in Mineralys Therapeutics in the second quarter worth about $2,721,000. TimesSquare Capital Management LLC purchased a new position in Mineralys Therapeutics during the 2nd quarter valued at $6,363,000. Bank of America Corp DE grew its position in Mineralys Therapeutics by 11.5% in the 1st quarter. Bank of America Corp DE now owns 1,100,372 shares of the company's stock valued at $29,809,000 after acquiring an additional 113,092 shares during the last quarter. Man Group plc purchased a new stake in Mineralys Therapeutics in the second quarter worth $1,609,000. Finally, Artia Global Partners LP increased its stake in Mineralys Therapeutics by 143.5% in the fourth quarter. Artia Global Partners LP now owns 137,800 shares of the company's stock worth $5,001,000 after purchasing an additional 81,200 shares during the period. 84.46% of the stock is owned by hedge funds and other institutional investors. Wall Street Analyst weigh in. MLYS has been the subject of several research reports. Jefferies Financial Group reissued a "hold" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Zacks Research upgraded Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, September 11th. Finally, HC Wainwright restated a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Mineralys Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $48.80. Discover more Financial News Self-Help & Motivational Mineralys Therapeutics company profile. Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company's research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension. Mineralys' lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Mineralys Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list. While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Continue following MarketBeat

MyChesCo
Sep 15th, 2026
Mineralys grants equity awards to two new employees.

Mineralys grants equity awards to two new employees. RADNOR, PA - Mineralys Therapeutics Inc. (Nasdaq: MLYS) granted stock options and restricted stock units covering a combined 52,080 shares to two newly hired non-executive employees as employment inducements under Nasdaq listing rules. The company's board compensation committee approved options covering 29,760 shares and restricted stock units covering 22,320 shares on Sept. 8. The awards were issued under Mineralys' 2025 Employment Inducement Incentive Award Plan and were granted as an inducement material to the employees joining the company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years. Twenty-five percent of the shares underlying the options will vest on the first anniversary of the Sept. 8 vesting commencement date, followed by 1/48th of the shares after each subsequent month, subject to continued employment. The restricted stock units also vest over four years, with 25% vesting on each of the first four anniversaries of the Sept. 8 commencement date, subject to continued service. Mineralys is developing treatments targeting hypertension and conditions associated with dysregulated aldosterone, including chronic kidney disease and obstructive sleep apnea. Its initial product candidate, lorundrostat, is an investigational oral aldosterone synthase inhibitor. The Radnor-based biopharmaceutical company was founded by Catalys Pacific. Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources - free for everyone. If you value that, click here to become a patron today. Discover more Download Interactive Maps Follow Federal Policy